Summary & Overview
CPT 78071: SPECT Parathyroid Imaging with Dual Tracers
CPT code 78071 denotes a nuclear medicine SPECT study targeted at the parathyroid glands that includes paired planar images after administration of two distinct radiopharmaceuticals, with optional subtraction imaging to localize abnormal tissue. This diagnostic service is important nationally for patients with suspected hyperparathyroidism or ectopic parathyroid tissue, informing surgical planning and management decisions. Payers commonly covering this service in national analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical purpose of CPT code 78071, typical settings where the service is rendered, and payer coverage context. The publication summarizes billing and coding considerations, common modifiers, and how this study fits within nuclear medicine service lines. It also highlights benchmarks and policy updates relevant to reimbursement and utilization where available, and explains clinical context for interpreting results and downstream care implications. Data not included in the input (such as specific ICD-10 pairings, associated taxonomies, and related codes) are noted as unavailable.
Billing Code Overview
CPT code 78071 describes a SPECT study of the parathyroid glands in which the provider acquires tomographic (SPECT) images and sets of planar images after administration of very small amounts of two different radiopharmaceuticals. The study typically includes comparison of the two tracer image sets and, when performed, a subtraction study in conjunction with the tomographic imaging to help identify abnormal parathyroid tissue.
-
Service type: Nuclear medicine imaging study combining SPECT and paired planar imaging with dual radiopharmaceuticals
-
Typical site of service: Hospital outpatient imaging department, freestanding imaging center, or other nuclear medicine facility
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45–70-year-old adult referred by an endocrinologist for localization of suspected hyperfunctioning parathyroid tissue after biochemical evidence of primary hyperparathyroidism (elevated serum calcium and parathyroid hormone). The patient arrives at an outpatient nuclear medicine or hospital radiology department. The nuclear medicine practitioner explains the SPECT parathyroid imaging procedure, reviews contraindications (pregnancy, recent iodine-based contrast in some protocols), and obtains informed consent. The technologist administers two small, sequential radiopharmaceuticals (commonly sestamibi and a second agent) and acquires planar images followed by SPECT/CT tomographic images. In cases requiring subtraction, images from the two tracers are digitally compared or subtracted to enhance detection of adenomas or hyperplastic glands. Images are processed, reviewed by the nuclear medicine physician, and a report is generated describing focal radiotracer uptake, laterality, size estimates, and correlation with prior ultrasound or CT if available. The findings guide surgical planning for parathyroidectomy or further observation, and the procedure is typically billed by the imaging facility and interpreting physician using 78071 with appropriate modifiers for professional/technical components or circumstances of service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component |